{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:58:40Z","timestamp":1792612720041,"version":"4.5.0"},"reference-count":336,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012899","name":"Lanzhou University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012899","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016321","name":"Lanzhou University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.apsb.2025.03.025","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:20:21Z","timestamp":1741879221000},"page":"2323-2350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["The neuroscience of cancer: Focus on neuropeptidergic systems"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7371-204X","authenticated-orcid":false,"given":"Zikai","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8011-2405","authenticated-orcid":false,"given":"Weilin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.03.025_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.apsb.2025.03.025_bib2","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049729","article-title":"Understanding and modeling nerve-cancer interactions","volume":"16","author":"Le","year":"2023","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.apsb.2025.03.025_bib3","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.humpath.2014.02.009","article-title":"Biologic correlates and significance of axonogenesis in prostate cancer","volume":"45","author":"Olar","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41598-020-58425-5","article-title":"Innervation of papillary thyroid cancer and its association with extra-thyroidal invasion","volume":"10","author":"Rowe","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib5","article-title":"Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.03.025_bib6","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.molonc.2015.05.001","article-title":"Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer","volume":"9","author":"Pundavela","year":"2015","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib7","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1101\/gad.352288.124","article-title":"Cancer neuroscience at the brain-body interface","volume":"38","author":"Borniger","year":"2024","journal-title":"Genes Dev"},{"key":"10.1016\/j.apsb.2025.03.025_bib8","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/ijms18030507","article-title":"Role of nerve growth factor (NGF) and miRNAs in epithelial ovarian cancer","volume":"18","author":"Retamales-Ortega","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/1567205016666190408123947","article-title":"Is brain-derived neurotrophic factor: a common link between neurodegenerative disorders and cancer?.","volume":"16","author":"Khosla","year":"2019","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s41232-023-00300-7","article-title":"Testosterone upregulates glial cell line-derived neurotrophic factor (GDNF) and promotes neuroinflammation to enhance glioma cell survival and proliferation","volume":"43","author":"Kanwore","year":"2023","journal-title":"Inflamm Regen"},{"key":"10.1016\/j.apsb.2025.03.025_bib11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4161\/cam.4.1.10882","article-title":"Guidance molecules in lung cancer","volume":"4","author":"Nasarre","year":"2010","journal-title":"Cell Adhes Migr"},{"key":"10.1016\/j.apsb.2025.03.025_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41388-019-1006-0","article-title":"Neurotransmitters: emerging targets in cancer","volume":"39","author":"Jiang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.03.025_bib13","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ijc.20948","article-title":"Neuropeptide Y receptors in renal cell carcinomas and nephroblastomas","volume":"115","author":"K\u00f6rner","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/labinvest.3700009","article-title":"Neuropeptide Y receptor expression in human primary ovarian neoplasms","volume":"84","author":"K\u00f6rner","year":"2004","journal-title":"Lab Invest"},{"key":"10.1016\/j.apsb.2025.03.025_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bjc.1996.60","article-title":"The absence of autonomic perivascular nerves in human colorectal liver metastases","volume":"73","author":"Ashraf","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib16","article-title":"Neuropeptides in cancer: friend and foe?.","volume":"6","author":"Wu","year":"2022","journal-title":"Adv Biol(Weinh)"},{"key":"10.1016\/j.apsb.2025.03.025_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41419-021-04485-y","article-title":"Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.03.025_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1474-4422(03)00482-4","article-title":"Neuropeptides: opportunities for drug discovery","volume":"2","author":"H\u00f6kfelt","year":"2003","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2025.03.025_bib19","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0166-2236(00)02001-4","article-title":"Neuropeptides: brain messengers of many faces","volume":"24","author":"Gozes","year":"2001","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0889-8529(18)30079-3","article-title":"Proopiomelanocortin-derived peptides","volume":"23","author":"Bertagna","year":"1994","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.apsb.2025.03.025_bib21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/er.2011-1016","article-title":"Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research","volume":"33","author":"B\u00f6hm","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1152\/physrev.00024.2017","article-title":"POMC: the physiological power of hormone processing","volume":"98","author":"Harno","year":"2018","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/298065a0","article-title":"Neuropeptide coexistence in human cortical neurones","volume":"298","author":"Vincent","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib24","article-title":"NeuroPep: a comprehensive resource of neuropeptides","volume":"2015","author":"Wang","year":"2015","journal-title":"Database J Biol Databases Curation"},{"key":"10.1016\/j.apsb.2025.03.025_bib25","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3276383","article-title":"The role of hypothalamic neuropeptides in neurogenesis and neuritogenesis","volume":"2016","author":"Bakos","year":"2016","journal-title":"Neural Plast"},{"key":"10.1016\/j.apsb.2025.03.025_bib26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0028-3908(00)00010-1","article-title":"Neuropeptides\u2014an overview","volume":"39","author":"H\u00f6kfelt","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.apsb.2025.03.025_bib27","first-page":"1","article-title":"G protein-coupled receptors (GPCRs): advances in structures, mechanisms, and drug discovery","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.03.025_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15707-9","article-title":"Visualizing the GPCR network: classification and evolution","volume":"7","author":"Hu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib29","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/aps.2011.170","article-title":"Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors","volume":"33","author":"Pal","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.03.025_bib30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0163-7258(03)00038-X","article-title":"Evolution, structure, and activation mechanism of family 3\/C G-protein-coupled receptors","volume":"98","author":"Pin","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.03.025_bib31","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/aps.2011.186","article-title":"Structure and ligand recognition of class C GPCRs","volume":"33","author":"Chun","year":"2012","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2025.03.025_bib32","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.119.117986","article-title":"Molecular pharmacology of class F receptor activation","volume":"97","author":"Kozielewicz","year":"2020","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib33","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1126\/science.1071550","article-title":"G protein pathways","volume":"296","author":"Neves","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.03.025_bib34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/1389450013348452","article-title":"Convergence of PKC-dependent kinase signal cascades on NMDA receptors","volume":"2","author":"MacDonald","year":"2001","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.apsb.2025.03.025_bib35","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1158\/1078-0432.CCR-11-0641","article-title":"Molecular pathways: beta-adrenergic signaling in cancer","volume":"18","author":"Cole","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/24884","article-title":"Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP","volume":"396","author":"de Rooij","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1040-7952(97)80019-5","article-title":"Structure, function, and regulation of human cAMP-dependent protein kinases","volume":"31","author":"Task\u00e9n","year":"1997","journal-title":"Adv Second Messenger Phosphoprotein Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib38","doi-asserted-by":"crossref","first-page":"16239","DOI":"10.1074\/jbc.RA120.013756","article-title":"CaMKK2 is inactivated by cAMP\u2013PKA signaling and 14-3-3 adaptor proteins","volume":"295","author":"Langendorf","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib39","doi-asserted-by":"crossref","first-page":"18431","DOI":"10.1016\/S0021-9258(18)55078-X","article-title":"The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase A","volume":"266","author":"Rehfuss","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF\u2013MEK\u2013ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib41","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/sj.onc.1204188","article-title":"Rho GTPase-dependent transformation by G protein-coupled receptors","volume":"20","author":"Whitehead","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.03.025_bib42","first-page":"1449","article-title":"ADP-ribosylation of the rhoA gene product by botulinum C3 exoenzyme causes Swiss 3T3 cells to accumulate in the G1 phase of the cell cycle","volume":"8","author":"Yamamoto","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.03.025_bib43","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2174\/138945011795906534","article-title":"Rho GTPase effector functions in tumor cell invasion and metastasis","volume":"12","author":"Baranwal","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.apsb.2025.03.025_bib44","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.nut.2004.06.021","article-title":"Neuropeptide Y, \u03b1-melanocyte\u2013stimulating hormone, and monoamines in food intake regulation","volume":"21","author":"Ramos","year":"2005","journal-title":"Nutrition"},{"key":"10.1016\/j.apsb.2025.03.025_bib45","first-page":"1411","article-title":"Regulation of feeding-related behaviors by arcuate neuropeptide Y neurons","volume":"160","author":"Zhang","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib46","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1523\/JNEUROSCI.3249-08.2009","article-title":"Neuromedin B and gastrin-releasing peptide excite arcuate nucleus neuropeptide Y neurons in a novel transgenic mouse expressing strong Renilla green fluorescent protein in NPY neurons","volume":"29","author":"van den Pol","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.npep.2012.08.005","article-title":"Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut\u2013brain axis","volume":"46","author":"Holzer","year":"2012","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib48","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0196-9781(00)00313-2","article-title":"Peptidergic regulation of gastrointestinal motility in rodents","volume":"21","author":"Fujimiya","year":"2000","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib49","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.1010529108","article-title":"Normal gut microbiota modulates brain development and behavior","volume":"108","author":"Diaz","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.03.025_bib50","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.smrv.2009.09.001","article-title":"Neuropeptide Y and sleep","volume":"14","author":"Dyzma","year":"2010","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq4515","article-title":"GnRH replacement rescues cognition in Down syndrome","volume":"377","author":"Manfredi-Lozano","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.03.025_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13006","article-title":"Neuropeptide Y suppresses thermogenic and cardiovascular sympathetic nerve activity via Y1 receptors in the paraventricular nucleus and dorsomedial hypothalamus","volume":"33","author":"Shi","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.it.2016.10.001","article-title":"Nociceptor sensory neuron-immune interactions in pain and inflammation","volume":"38","author":"Pinho-Ribeiro","year":"2017","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib54","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1046\/j.1460-9568.1998.00172.x","article-title":"Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos","volume":"10","author":"Gressens","year":"1998","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib55","doi-asserted-by":"crossref","first-page":"C1271","DOI":"10.1152\/ajpcell.1994.266.5.C1271","article-title":"Neuropeptide Y stimulates hypertrophy of adult ventricular cardiomyocytes","volume":"266","author":"Millar","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.apsb.2025.03.025_bib56","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.peptides.2016.05.001","article-title":"Restraining the trophic effects of gastrin","volume":"82","author":"Dockray","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/biom12020156","article-title":"Adrenomedullin: not just another gastrointestinal peptide","volume":"12","author":"Mart\u00ednez-Herrero","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2025.03.025_bib58","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ijc.22596","article-title":"Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion","volume":"121","author":"Keleg","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib59","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/eje.0.1440517","article-title":"Adrenomedullin, a new peptide, in patients with insulinoma","volume":"144","author":"Letizia","year":"2001","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib60","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac009","article-title":"Other markers of medullary thyroid cancer, not only calcitonin","volume":"188","author":"Censi","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40610-017-0071-9","article-title":"The role of the calcitonin peptide family in prostate cancer and bone metastasis","volume":"3","author":"Warrington","year":"2017","journal-title":"Curr Mol Biol Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.705499","article-title":"Update on the role of neuropeptide Y and other related factors in breast cancer and osteoporosis","volume":"12","author":"Lin","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib63","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0197-0186(99)00096-0","article-title":"Expression of neuropeptide Y by glutamatergic stimulation in rat C6 glioma cells","volume":"36","author":"Kim","year":"2000","journal-title":"Neurochem Int"},{"key":"10.1016\/j.apsb.2025.03.025_bib64","doi-asserted-by":"crossref","first-page":"9962","DOI":"10.3390\/ijms24129962","article-title":"Neuropeptide Y peptide family and cancer: antitumor therapeutic strategies","volume":"24","author":"S\u00e1nchez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.peptides.2006.08.037","article-title":"NPY receptors in human cancer: a review of current knowledge","volume":"28","author":"K\u00f6rner","year":"2007","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib66","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1158\/1078-0432.CCR-22-1500","article-title":"NPY methylated ctDNA is a promising biomarker for treatment response monitoring in metastatic colorectal cancer","volume":"29","author":"Janssens","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.npep.2015.10.005","article-title":"Neuropeptide Y (NPY) in tumor growth and progression: lessons learned from pediatric oncology","volume":"55","author":"Tilan","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib68","first-page":"213","article-title":"Plasma neuropeptide Y (NPY) levels in patients with gastric and colorectal carcinomas","volume":"20","author":"Li","year":"1998","journal-title":"Chin J Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib69","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/apm.12886","article-title":"Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer","volume":"126","author":"Kristensen","year":"2018","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"},{"key":"10.1016\/j.apsb.2025.03.025_bib70","doi-asserted-by":"crossref","first-page":"5803","DOI":"10.1007\/s00432-022-04540-x","article-title":"Neuropeptide Y and its receptors in prostate cancer: associations with cancer invasiveness and perineural spread","volume":"149","author":"Sigorski","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jss.2017.11.010","article-title":"Expression of neuropeptide Y and its receptors Y1 and Y2 in pancreatic intraepithelial neoplasia and invasive pancreatic cancer in a transgenic mouse model and human samples of pancreatic cancer","volume":"223","author":"Waldmann","year":"2018","journal-title":"J Surg Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib72","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3892\/mmr.2021.12560","article-title":"Opioids in cancer: the \u03ba-opioid receptor","volume":"25","author":"Zhou","year":"2022","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib73","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11912-021-01107-w","article-title":"Targeting the mu-opioid receptor for cancer treatment","volume":"23","author":"Zhang","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib74","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s11912-022-01295-z","article-title":"Antagonists of the mu-opioid receptor in the cancer patient: fact or fiction?.","volume":"24","author":"Belltall","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib75","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1002\/cncr.29460","article-title":"The mu opioid receptor: a new target for cancer therapy?.","volume":"121","author":"Singleton","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib76","doi-asserted-by":"crossref","first-page":"9307","DOI":"10.1007\/s11033-022-07771-w","article-title":"The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells","volume":"49","author":"Momen Razmgah","year":"2022","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib77","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cge.13750","article-title":"New insight into the role of substance P\/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs","volume":"98","author":"Ebrahimi","year":"2020","journal-title":"Clin Genet"},{"key":"10.1016\/j.apsb.2025.03.025_bib78","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3748\/wjg.v20.i9.2321","article-title":"Involvement of substance P and the NK-1 receptor in pancreatic cancer","volume":"20","author":"Mu\u00f1oz","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2025.03.025_bib79","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S1078-1439(98)00028-3","article-title":"Suppression of the growth and invasiveness of human prostate cancer cells in vitro by neuropeptide antagonist substance P analogues","volume":"4","author":"Iwamura","year":"1998","journal-title":"Urol Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1085245","article-title":"Targeted alpha therapy for glioblastoma","volume":"9","author":"Kunikowska","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib81","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib83","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.molmed.2022.04.005","article-title":"Nerve-stem cell crosstalk in skin regeneration and diseases","volume":"28","author":"Peng","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib84","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2025.03.025_bib85","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41467-020-20717-9","article-title":"Adrenomedullin\u2013CALCRL axis controls relapse-initiating drug tolerant acute myeloid leukemia cells","volume":"12","author":"Larrue","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.03.025_bib86","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1038\/s41375-019-0505-x","article-title":"The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia","volume":"33","author":"Angenendt","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.apsb.2025.03.025_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.684396","article-title":"Adrenomedullin expression characterizes leukemia stem cells and associates with an inflammatory signature in acute myeloid leukemia","volume":"11","author":"Simonetti","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib88","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4161\/cbt.22959","article-title":"Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells","volume":"14","author":"Coffman","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.apsb.2025.03.025_bib89","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/1878-0261.12609","article-title":"Endothelin-converting enzyme-1c promotes stem cell traits and aggressiveness in colorectal cancer cells","volume":"14","author":"P\u00e9rez-Moreno","year":"2020","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib90","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.18632\/oncotarget.1482","article-title":"Bone marrow adipocytes promote tumor growth in bone via FABP4-dependent mechanisms","volume":"4","author":"Herroon","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.03.025_bib91","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.18632\/oncotarget.6643","article-title":"Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop","volume":"7","author":"Tang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.03.025_bib92","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","article-title":"Neuropeptide substance P and the immune response","volume":"73","author":"Mashaghi","year":"2016","journal-title":"Cell Mol Life Sci CMLS"},{"key":"10.1016\/j.apsb.2025.03.025_bib93","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2249.2007.03514.x","article-title":"Substance P regulates macrophage inflammatory protein 3alpha\/chemokine C\u2013C ligand 20 (CCL20) with heme oxygenase-1 in human periodontal ligament cells","volume":"150","author":"Lee","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib94","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0165-5728(02)00277-1","article-title":"Substance P up-regulates macrophage inflammatory protein-1beta expression in human T lymphocytes","volume":"131","author":"Guo","year":"2002","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib95","first-page":"27","article-title":"Stimulation of CCL2 (MCP-1) and CCL2 mRNA by substance P in LAD2 human mast cells","volume":"154","author":"Castellani","year":"2009","journal-title":"Transl Res J Lab Clin Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib96","first-page":"3871","article-title":"Substance P differentially stimulates IL-8 synthesis in human corneal epithelial cells","volume":"41","author":"Tran","year":"2000","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib97","first-page":"7006","article-title":"In vivo signaling through the neurokinin 1 receptor favors transgene expression by Langerhans cells and promotes the generation of Th1- and Tc1-biased immune responses","volume":"178","author":"Mathers","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.apsb.2025.03.025_bib98","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1182\/blood-2013-02-483354","article-title":"Harnessing DCs by substance P","volume":"121","author":"Takashima","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.03.025_bib99","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1182\/blood-2012-07-446054","article-title":"Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12","volume":"121","author":"Janelsins","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.03.025_bib100","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1182\/blood.V86.2.482.bloodjournal862482","article-title":"Substance P (SP) mediates production of stem cell factor and interleukin-1 in bone marrow stroma: potential autoregulatory role for these cytokines in SP receptor expression and induction","volume":"86","author":"Rameshwar","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2025.03.025_bib101","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/cbin.10158","article-title":"Neuropeptide SP activates the WNT signal transduction pathway and enhances the proliferation of bone marrow stromal stem cells","volume":"37","author":"Mei","year":"2013","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.apsb.2025.03.025_bib102","first-page":"3498","article-title":"Substance P enhances IL-2 expression in activated human T cells","volume":"148","author":"Calvo","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.apsb.2025.03.025_bib103","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#","article-title":"Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation","volume":"29","author":"Lambrecht","year":"1999","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib104","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-3083.2011.02550.x","article-title":"Regulation of NK92-MI cell cytotoxicity by substance P","volume":"74","author":"Fu","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib105","first-page":"2118","article-title":"Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca2+ concentration and inositol phosphate formation","volume":"141","author":"Serra","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.apsb.2025.03.025_bib106","first-page":"359","article-title":"Activation of human neutrophils by substance P: effect on FMLP-stimulated oxidative and arachidonic acid metabolism and on antibody-dependent cell-mediated cytotoxicity","volume":"68","author":"Wozniak","year":"1989","journal-title":"Immunology"},{"key":"10.1016\/j.apsb.2025.03.025_bib107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0014-2999(83)90511-3","article-title":"Activation of macrophages by substance P: induction of oxidative burst and thromboxane release","volume":"89","author":"Hartung","year":"1983","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib108","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1398-9995.1995.tb01157.x","article-title":"Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production","volume":"50","author":"Murris-Espin","year":"1995","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.03.025_bib109","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1365-2567.2010.03296.x","article-title":"Substance P primes lipoteichoic acid- and Pam3CysSerLys4-mediated activation of human mast cells by up-regulating Toll-like receptor 2","volume":"131","author":"Tancowny","year":"2010","journal-title":"Immunology"},{"key":"10.1016\/j.apsb.2025.03.025_bib110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/1523-1747.ep12330326","article-title":"Skin-nervous system interactions","volume":"106","author":"Ansel","year":"1996","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.03.025_bib111","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0165-5728(90)90084-Z","article-title":"Effects of capsaicin treatment on immunoglobulin secretion in the rat: further evidence for involvement of tachykinin-containing afferent nerves","volume":"26","author":"Eglezos","year":"1990","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib112","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1165\/rcmb.4635","article-title":"Airway smooth muscle cells express functional neurokinin-1 receptors and the nerve-derived preprotachykinin-a gene: regulation by passive sensitization","volume":"28","author":"Maghni","year":"2003","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib113","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0026-2862(90)90024-L","article-title":"Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells","volume":"40","author":"Ziche","year":"1990","journal-title":"Microvasc Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib114","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/icb.2010.29","article-title":"New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes","volume":"88","author":"Jimeno","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib115","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1196\/annals.1317.077","article-title":"VIP protects Th2 cells by downregulating granzyme B expression","volume":"1070","author":"Sharma","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib116","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-024-08049-w","article-title":"Neuropeptide signalling orchestrates T cell differentiation","volume":"635","author":"Hou","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib117","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.biocel.2008.01.022","article-title":"The endothelin axis in cancer","volume":"40","author":"Bagnato","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib118","first-page":"1497","article-title":"Endothelin-1-induced endothelial microvesicles impair endothelial cell function","volume":"128","author":"Brewster","year":"1985","journal-title":"J Appl Physiol Bethesda Md"},{"key":"10.1016\/j.apsb.2025.03.025_bib119","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.peptides.2014.10.018","article-title":"The effect of neuropeptide Y on brown-like adipocyte's differentiation and activation","volume":"63","author":"Wan","year":"2015","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib120","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib121","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/cne.22025","article-title":"Leptin targets in the mouse brain","volume":"514","author":"Scott","year":"2009","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.apsb.2025.03.025_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diab.47.1.1","article-title":"Evidence against a direct effect of leptin on glucose transport in skeletal muscle and adipocytes","volume":"47","author":"Zierath","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.apsb.2025.03.025_bib123","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1677\/joe.0.1750735","article-title":"Leptin controls the fate of fatty acids in isolated rat white adipocytes","volume":"175","author":"William","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib124","doi-asserted-by":"crossref","first-page":"E1230","DOI":"10.1152\/ajpendo.90927.2008","article-title":"Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion","volume":"296","author":"Lee","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.apsb.2025.03.025_bib125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0014-5793(01)02113-5","article-title":"Growth factor-dependent signaling and cell cycle progression","volume":"490","author":"Jones","year":"2001","journal-title":"FEBS Lett"},{"key":"10.1016\/j.apsb.2025.03.025_bib126","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1659742","article-title":"Growth factors and cancer","volume":"254","author":"Aaronson","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.03.025_bib127","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/316823a0","article-title":"Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer","volume":"316","author":"Cuttitta","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib128","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/onc.2014.104","article-title":"Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma","volume":"34","author":"Castellone","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2025.03.025_bib129","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2019.118625","article-title":"Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism","volume":"1867","author":"Lee","year":"2020","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib130","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-12-4573","article-title":"Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer","volume":"73","author":"Garcia-Recio","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib131","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/1040-8428(96)00204-1","article-title":"Bombesin-like peptides and cancer","volume":"23","author":"Preston","year":"1996","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.apsb.2025.03.025_bib132","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/NEN.0b013e318180e618","article-title":"Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors","volume":"67","author":"K\u00f6rner","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.apsb.2025.03.025_bib133","doi-asserted-by":"crossref","first-page":"C1078","DOI":"10.1152\/ajpcell.00358.2010","article-title":"Neuropeptide Y inhibits cholangiocarcinoma cell growth and invasion","volume":"300","author":"DeMorrow","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.apsb.2025.03.025_bib134","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.mce.2008.02.002","article-title":"Antitumor effects of somatostatin","volume":"286","author":"Pyronnet","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib135","first-page":"1993","article-title":"A hallmark of immunoreceptor, the tyrosine-based inhibitory motif ITIM, is present in the G protein-coupled receptor OX1R for orexins and drives apoptosis: a novel mechanism","volume":"22","author":"Voisin","year":"2008","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib136","first-page":"4069","article-title":"Discovery of a functional immunoreceptor tyrosine-based switch motif in a 7-transmembrane-spanning receptor: role in the orexin receptor OX1R-driven apoptosis","volume":"23","author":"El Firar","year":"2009","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib137","doi-asserted-by":"crossref","first-page":"45875","DOI":"10.1074\/jbc.M404136200","article-title":"Orexins acting at native OX1 receptor in colon cancer and neuroblastoma cells or at recombinant OX1 receptor suppress cell growth by inducing apoptosis","volume":"279","author":"Rouet-Benzineb","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib138","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fendo.2018.00647","article-title":"The orexin-A-regulated Akt\/mTOR pathway promotes cell proliferation through inhibiting apoptosis in pancreatic cancer cells","volume":"9","author":"Suo","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib139","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107837","article-title":"Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2\/Bax\/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity","volume":"98","author":"Zhang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108933","article-title":"Methionine enkephalin inhibited cervical carcinoma via apoptosis promotion and reduction of myeloid derived suppressor cell infiltrated in tumor","volume":"110","author":"Qu","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.07.024","article-title":"Involvement of substance P and the NK-1 receptor in cancer progression","volume":"48","author":"Mu\u00f1oz","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib142","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/cancers12092682","article-title":"The neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?.","volume":"12","author":"Mu\u00f1oz","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.03.025_bib143","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8808214","article-title":"Aprepitant promotes caspase-dependent apoptotic cell death and G2\/M arrest through PI3K\/Akt\/NF-\u03baB axis in cancer stem-like esophageal squamous cell carcinoma spheres","volume":"2021","author":"Javid","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apsb.2025.03.025_bib144","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejphar.2016.02.026","article-title":"Cross-talk between 5-hydroxytryptamine and substance P in the melanogensis and apoptosis of B16F10 melanoma cells","volume":"775","author":"Zhou","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib145","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0002-9440(10)65006-7","article-title":"Openings between defective endothelial cells explain tumor vessel leakiness","volume":"156","author":"Hashizume","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib146","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/ijc.2910610608","article-title":"Substance-P receptors in human primary neoplasms: tumoral and vascular localization","volume":"61","author":"Hennig","year":"1995","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib147","first-page":"588","article-title":"Progressive loss of perivascular nerves adjacent to colorectal cancer","volume":"26","author":"Chamary","year":"2000","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib148","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1083\/jcb.200603152","article-title":"An antiangiogenic neurokinin-B\/thromboxane A2 regulatory axis","volume":"174","author":"Pal","year":"2006","journal-title":"J Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib149","doi-asserted-by":"crossref","first-page":"40713","DOI":"10.18632\/oncotarget.17250","article-title":"Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2025.03.025_bib150","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0167-0115(93)90435-B","article-title":"Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV","volume":"49","author":"Mentlein","year":"1993","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2025.03.025_bib151","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.yjmcc.2010.08.022","article-title":"Effects of neuropeptide Y on collateral development in a swine model of chronic myocardial ischemia","volume":"49","author":"Robich","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.apsb.2025.03.025_bib152","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1139\/y02-166","article-title":"Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system","volume":"81","author":"Pons","year":"2003","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib153","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0196-9781(93)90040-N","article-title":"Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells","volume":"14","author":"Zukowska-Grojec","year":"1993","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib154","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejphar.2016.02.033","article-title":"Neuropeptide Y is an angiogenic factor in cardiovascular regeneration","volume":"776","author":"Saraf","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S1050-1738(02)00232-3","article-title":"Neuropeptide Y: a novel mechanism for ischemic angiogenesis","volume":"13","author":"Zukowska","year":"2003","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib156","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3390\/biomedicines12030511","article-title":"Endothelin-1 and its role in cancer and potential therapeutic opportunities","volume":"12","author":"Harrison","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2025.03.025_bib157","first-page":"1","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2025.03.025_bib158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib159","first-page":"83","article-title":"Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis","volume":"9","author":"Leenders","year":"2002","journal-title":"Endothel J Endothel Cell Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib160","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/S0140-6736(07)60781-8","article-title":"Metastasis: recent discoveries and novel treatment strategies","volume":"369","author":"Eccles","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.03.025_bib161","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10555-020-09868-9","article-title":"KISS1 in metastatic cancer research and treatment: potential and paradoxes","volume":"39","author":"Ly","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib162","doi-asserted-by":"crossref","first-page":"647","DOI":"10.2353\/ajpath.2009.080685","article-title":"Transmembrane interactions are needed for KAI1\/CD82-mediated suppression of cancer invasion and metastasis","volume":"174","author":"Bari","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib163","doi-asserted-by":"crossref","first-page":"34631","DOI":"10.1074\/jbc.M104847200","article-title":"The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54","volume":"276","author":"Kotani","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib164","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bbrc.2004.01.021","article-title":"Metastin and its variant forms suppress migration of pancreatic cancer cells","volume":"315","author":"Masui","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2025.03.025_bib165","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-08-2907","article-title":"Overexpression of RhoA induces preneoplastic transformation of primary mammary epithelial cells","volume":"69","author":"Zhao","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib166","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jnci\/88.23.1731","article-title":"KiSS-1, a novel human malignant melanoma metastasis-suppressor gene","volume":"88","author":"Lee","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.apsb.2025.03.025_bib167","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2174\/1568026616666160212123309","article-title":"Kisspeptin mediated signaling in cancer","volume":"16","author":"Jabeen","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib168","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fendo.2018.00115","article-title":"Kisspeptin and cancer: molecular interaction, biological functions, and future perspectives","volume":"9","author":"Ciaramella","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib169","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fendo.2018.00437","article-title":"KISS1\/KISS1R in cancer: friend or foe?.","volume":"9","author":"Guzman","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib170","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ar.20950","article-title":"Expression of KiSS-1 gene and its role in invasion and metastasis of human hepatocellular carcinoma","volume":"292","author":"Shengbing","year":"2007","journal-title":"Anat Rec Hoboken NJ"},{"key":"10.1016\/j.apsb.2025.03.025_bib171","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1210\/en.2012-2164","article-title":"KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells","volume":"154","author":"Cvetkovic","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib172","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.cellsig.2015.12.010","article-title":"KISS1R signaling promotes invadopodia formation in human breast cancer cell via \u03b2-arrestin2\/ERK","volume":"28","author":"Goertzen","year":"2016","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2025.03.025_bib173","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021599","article-title":"GPR54 (KISS1R) transactivates EGFR to promote breast cancer cell invasiveness","volume":"6","author":"Zajac","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.03.025_bib174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellsig.2017.10.002","article-title":"KiSS1 gene as a novel mediator of TGF\u03b2-mediated cell invasion in triple negative breast cancer","volume":"42","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2025.03.025_bib175","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/0008-5472.CAN-11-0329","article-title":"Haploinsufficiency in the prometastasis Kiss1 receptor Gpr54 delays breast tumor initiation, progression and lung metastasis","volume":"71","author":"Cho","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib176","doi-asserted-by":"crossref","DOI":"10.1038\/srep46525","article-title":"G protein-coupled KISS1 receptor is overexpressed in triple negative breast cancer and promotes drug resistance","volume":"7","author":"Blake","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib177","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1158\/0008-5472.CAN-13-2053","article-title":"Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors","volume":"74","author":"Rani","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib178","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s13046-021-02073-8","article-title":"Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor","volume":"40","author":"Przygodzka","year":"2021","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.apsb.2025.03.025_bib179","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1038\/s41467-022-29898-x","article-title":"Hypoxia-activated neuropeptide Y\/Y5 receptor\/RhoA pathway triggers chromosomal instability and bone metastasis in Ewing sarcoma","volume":"13","author":"Lu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.03.025_bib180","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.euo.2019.05.001","article-title":"Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications","volume":"2","author":"Alshalalfa","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib181","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1158\/1541-7786.MCR-12-0609","article-title":"Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells","volume":"11","author":"Li","year":"2013","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.apsb.2025.03.025_bib182","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13193-020-01210-7","article-title":"Neuropeptide substance P enhances inflammation-mediated tumor signaling pathways and migration and proliferation of head and neck cancers","volume":"12","author":"Singh","year":"2021","journal-title":"Indian J Surg Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib183","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13046-018-0674-x","article-title":"Role of the nervous system in cancer metastasis","volume":"37","author":"Kuol","year":"2018","journal-title":"J Exp Clin Cancer Res CR"},{"key":"10.1016\/j.apsb.2025.03.025_bib184","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41586-024-07767-5","article-title":"Neuronal substance P drives metastasis through an extracellular RNA\u2013TLR7 axis","volume":"633","author":"Padmanaban","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib185","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41577-019-0147-2","article-title":"Pain and immunity: implications for host defence","volume":"19","author":"Baral","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib186","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000236977","article-title":"Neuropeptide signaling of lymphocytes in immunological responses","volume":"107","author":"Goetzl","year":"2009","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib187","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1094-5539(03)00049-X","article-title":"Calcitonin gene-related peptide as inflammatory mediator","volume":"16","author":"Springer","year":"2003","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.03.025_bib188","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/13892037113149990046","article-title":"Antiinflammatory activities of CGRP modulating innate immune responses in health and disease","volume":"14","author":"Holzmann","year":"2013","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib189","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.molimm.2017.08.020","article-title":"Calcitonin gene-related peptide exerts anti-inflammatory property through regulating murine macrophages polarization in vitro","volume":"91","author":"Duan","year":"2017","journal-title":"Mol Immunol"},{"key":"10.1016\/j.apsb.2025.03.025_bib190","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/s41374-019-0364-0","article-title":"RAMP1 signaling in immune cells regulates inflammation-associated lymphangiogenesis","volume":"100","author":"Tsuru","year":"2020","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib191","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202200019","article-title":"Sensory neurotransmitter calcitonin gene-related peptide modulates tumor growth and lymphocyte infiltration in oral squamous cell carcinoma","volume":"6","author":"McIlvried","year":"2022","journal-title":"Adv Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib192","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-022-05374-w","article-title":"Nociceptor neurons affect cancer immunosurveillance","volume":"611","author":"Balood","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.03.025_bib193","first-page":"950","article-title":"Interleukin 12 and antigen independently induce substance P receptor expression in T cells in murine schistosomiasis mansoni","volume":"15","author":"Blum","year":"2001","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib194","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.2741\/2426","article-title":"Tachykinins and hematopoietic stem cell functions: implications in clinical disorders and tissue regeneration","volume":"12","author":"Murthy","year":"2007","journal-title":"Front Biosci J Virtual Libr"},{"key":"10.1016\/j.apsb.2025.03.025_bib195","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.imlet.2003.09.004","article-title":"Neurotransmitters regulate the migration and cytotoxicity in natural killer cells","volume":"90","author":"Lang","year":"2003","journal-title":"Immunol Lett"},{"key":"10.1016\/j.apsb.2025.03.025_bib196","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2353\/ajpath.2006.060358","article-title":"An in vitro model of morphine withdrawal manifests the enhancing effect on human immunodeficiency virus infection of human T lymphocytes through the induction of substance P","volume":"169","author":"Wang","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib197","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.03.025_bib198","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171048","article-title":"Substance P reversibly compromises the integrity and function of blood\u2013brain barrier","volume":"167","author":"Gao","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib199","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/cbf.1587","article-title":"Up-regulation of the tight-junction protein ZO-1 by substance P and IGF-1 in A431 cells","volume":"27","author":"Ko","year":"2009","journal-title":"Cell Biochem Funct"},{"key":"10.1016\/j.apsb.2025.03.025_bib200","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00000441-198805000-00008","article-title":"Review: interactions between the blood-brain barrier and endogenous peptides: emerging clinical implications","volume":"295","author":"Banks","year":"1988","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib201","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00726-006-0335-9","article-title":"The role of substance P in stress and anxiety responses","volume":"31","author":"Ebner","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.apsb.2025.03.025_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2019.101993","article-title":"Substance P: a neuropeptide involved in the psychopathology of anxiety disorders","volume":"79","author":"Iftikhar","year":"2020","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib203","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000125544","article-title":"Substance P stimulates arginine vasopressin and inhibits adrenocorticotropin release in vivo in the rat","volume":"52","author":"Chowdrey","year":"1990","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib204","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.biopsych.2005.07.013","article-title":"Lack of efficacy of the substance P (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder","volume":"59","author":"Keller","year":"2006","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.apsb.2025.03.025_bib205","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.npp.1300260","article-title":"Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression","volume":"29","author":"Kramer","year":"2004","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib206","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.brainres.2006.04.026","article-title":"CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide Y levels in severe major depressive disorder","volume":"1095","author":"Hou","year":"2006","journal-title":"Brain Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib207","doi-asserted-by":"crossref","first-page":"12852","DOI":"10.1073\/pnas.220232997","article-title":"Behavioral insensitivity to restraint stress, absent fear suppression of behavior and impaired spatial learning in transgenic rats with hippocampal neuropeptide Y overexpression","volume":"97","author":"Thorsell","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.03.025_bib208","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/mco2.164","article-title":"Targeting cancer cachexia: molecular mechanisms and clinical study","volume":"3","author":"Wang","year":"2022","journal-title":"MedComm"},{"key":"10.1016\/j.apsb.2025.03.025_bib209","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0167-0115(98)00095-0","article-title":"NPY and food intake: discrepancies in the model","volume":"75\u201376","author":"Woods","year":"1998","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2025.03.025_bib210","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0196-9781(96)00108-8","article-title":"Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y","volume":"17","author":"Chance","year":"1996","journal-title":"Peptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib211","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(03)01247-6","article-title":"Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies","volume":"4","author":"Laviano","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib212","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1097\/01.mco.0000134363.53782.cb","article-title":"Cancer anorexia-cachexia syndrome: cytokines and neuropeptides","volume":"7","author":"Ramos","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.apsb.2025.03.025_bib213","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1159\/000530804","article-title":"Alpha-melanocyte-stimulating hormone-mediated appetite regulation in the central nervous system","volume":"113","author":"Wu","year":"2023","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib214","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1210\/endo.142.8.8324","article-title":"Reversal of cancer anorexia by blockade of central melanocortin receptors in rats","volume":"142","author":"Wisse","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib215","first-page":"1432","article-title":"Role of the central melanocortin system in cachexia","volume":"61","author":"Marks","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib216","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0896-6273(00)80656-X","article-title":"Leptin activates hypothalamic CART neurons projecting to the spinal cord","volume":"21","author":"Elias","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.apsb.2025.03.025_bib217","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/1082","article-title":"Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons","volume":"1","author":"Hahn","year":"1998","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib218","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJM199007263230405","article-title":"Elevated circulating levels of tumor necrosis factor in severe chronic heart failure","volume":"323","author":"Levine","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib219","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1053\/euhj.1998.1446","article-title":"Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure","volume":"20","author":"Anker","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.apsb.2025.03.025_bib220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1161\/01.CIR.77.2.264","article-title":"Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities","volume":"77","author":"Lundin","year":"1988","journal-title":"Circulation"},{"key":"10.1016\/j.apsb.2025.03.025_bib221","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.apsb.2025.03.025_bib222","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.STR.25.4.904","article-title":"Does endothelin-1 play a role in the pathogenesis of cerebral vasospasm?.","volume":"25","author":"Cosentino","year":"1994","journal-title":"Stroke"},{"key":"10.1016\/j.apsb.2025.03.025_bib223","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1179\/1743132813Y.0000000246","article-title":"Neuropeptide Y\u2014an early biomarker for cerebral vasospasm after aneurysmal subarachnoid hemorrhage","volume":"35","author":"Schebesch","year":"2013","journal-title":"Neurol Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib224","article-title":"Update on prevalence of pain in patients with cancer: systematic review and meta-analysis","volume":"51","author":"Everdingen","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.apsb.2025.03.025_bib225","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S1357-2725(01)00031-0","article-title":"Substance p","volume":"33","author":"Harrison","year":"2001","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib226","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pain.2006.02.015","article-title":"Vasoactive intestinal peptide (VIP) is a modulator of joint pain in a rat model of osteoarthritis","volume":"123","author":"McDougall","year":"2006","journal-title":"Pain"},{"key":"10.1016\/j.apsb.2025.03.025_bib227","first-page":"1185","article-title":"The cholecystokinin type 2 receptor, a pharmacological target for pain management","volume":"14","author":"Bernard","year":"2021","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.apsb.2025.03.025_bib228","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1152\/physrev.00031.2013","article-title":"Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease","volume":"94","author":"Steinhoff","year":"2014","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib229","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neuroscience.2017.08.050","article-title":"Neuropeptide Y and its involvement in chronic pain","volume":"387","author":"Diaz-delCastillo","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.apsb.2025.03.025_bib230","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1523\/JNEUROSCI.14-08-04965.1994","article-title":"Inhibitory actions of delta 1-, delta 2-, and mu-opioid receptor agonists on excitatory transmission in lamina II neurons of adult rat spinal cord","volume":"14","author":"Glaum","year":"1994","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib231","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1523\/JNEUROSCI.20-23-08578.2000","article-title":"Postsynaptic signaling via the [mu]-opioid receptor: responses of dorsal horn neurons to exogenous opioids and noxious stimulation","volume":"20","author":"Trafton","year":"2000","journal-title":"J Neurosci Off J Soc Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib232","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55289","article-title":"Different neuronal populations mediate inflammatory pain analgesia by exogenous and endogenous opioids","volume":"9","author":"Zhang","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2025.03.025_bib233","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/add.15636","article-title":"Opioid use disorder and the brain: a clinical perspective","volume":"117","author":"Herlinger","year":"2022","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.apsb.2025.03.025_bib234","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addict Abingdon Engl"},{"issue":"Suppl 1","key":"10.1016\/j.apsb.2025.03.025_bib235","first-page":"S27","article-title":"Cardiac effects of opioid therapy","volume":"16","author":"Chen","year":"2015","journal-title":"Pain Med Malden Mass"},{"key":"10.1016\/j.apsb.2025.03.025_bib236","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/S0140-6736(19)32313-X","article-title":"Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial","volume":"394","author":"Sessler","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.apsb.2025.03.025_bib237","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SPC.0000000000000056","article-title":"Opioids and cancer recurrence","volume":"8","author":"Juneja","year":"2014","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.apsb.2025.03.025_bib238","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202300102","article-title":"The role of opioid receptors in cancer","volume":"7","author":"Bhoir","year":"2023","journal-title":"Adv Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib239","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.apsb.2020.04.014","article-title":"Novel opioid-neurotensin-based hybrid peptide with spinal long-lasting antinociceptive activity and a propensity to delay tolerance development","volume":"10","author":"Fr\u0105czek","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.03.025_bib240","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3390\/ijms20112780","article-title":"Molecular mechanisms of cancer-induced sleep disruption","volume":"20","author":"Walker","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib241","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.03.025_bib242","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.03.025_bib243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000514961","article-title":"Twenty-three years of hypocretins: the \u201cRosetta Stone\u201d of sleep\/arousal circuits","volume":"45","author":"de Lecea","year":"2021","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib244","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/cne.903190204","article-title":"The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization","volume":"319","author":"Bittencourt","year":"1992","journal-title":"J Comp Neurol"},{"key":"10.1016\/j.apsb.2025.03.025_bib245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2202-4-19","article-title":"A role of melanin-concentrating hormone producing neurons in the central regulation of paradoxical sleep","volume":"4","author":"Verret","year":"2003","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.apsb.2025.03.025_bib246","article-title":"Neuronal induction of bone\u2013fat imbalance through osteocyte neuropeptide Y","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib247","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.npep.2015.12.008","article-title":"Neuropeptide Y stimulates osteoblastic differentiation and VEGF expression of bone marrow mesenchymal stem cells related to canonical Wnt signaling activating in vitro","volume":"56","author":"Liu","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib248","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.npep.2016.09.005","article-title":"Neuropeptide Y accelerates post-fracture bone healing by promoting osteogenesis of mesenchymal stem cells","volume":"60","author":"Gu","year":"2016","journal-title":"Neuropeptides"},{"key":"10.1016\/j.apsb.2025.03.025_bib249","article-title":"Neuropeptide Y and metabolism syndrome: an update on perspectives of clinical therapeutic intervention strategies","volume":"9","author":"Huang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib250","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1258\/ebm.2010.009334","article-title":"Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome","volume":"235","author":"Rasmusson","year":"2010","journal-title":"Exp Biol Med Maywood NJ"},{"key":"10.1016\/j.apsb.2025.03.025_bib251","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/embor.2012.174","article-title":"Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis","volume":"13","author":"Varela","year":"2012","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2025.03.025_bib252","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cmet.2012.07.004","article-title":"Selective insulin and leptin resistance in metabolic disorders","volume":"16","author":"K\u00f6nner","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2025.03.025_bib253","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cmet.2005.11.013","article-title":"Insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes","volume":"3","author":"Gelling","year":"2006","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2025.03.025_bib254","first-page":"137","article-title":"Region-specific neuropeptide Y overflows at rest and during sympathetic activation in humans","volume":"29","author":"Morris","year":"1997","journal-title":"Hypertens Dallas Tex 1979"},{"key":"10.1016\/j.apsb.2025.03.025_bib255","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.3390\/cells10112908","article-title":"Novel peptide therapeutic approaches for cancer treatment","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2025.03.025_bib256","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00726-005-0289-3","article-title":"Strategies to improve plasma half life time of peptide and protein drugs","volume":"30","author":"Werle","year":"2006","journal-title":"Amino Acids"},{"key":"10.1016\/j.apsb.2025.03.025_bib257","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1039\/D0BM01358G","article-title":"Recent progress of therapeutic peptide based nanomaterials: from synthesis and self-assembly to cancer treatment","volume":"8","author":"Guo","year":"2020","journal-title":"Biomater Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib258","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.2174\/0929866521666140807114240","article-title":"Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles","volume":"21","author":"Patel","year":"2014","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.apsb.2025.03.025_bib259","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.4155\/fmc.12.75","article-title":"Flexible or fixed: a comparative review of linear and cyclic cancer-targeting peptides","volume":"4","author":"Roxin","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/s12885-023-10954-8","article-title":"Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation","volume":"23","author":"Cao","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib261","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3390\/cancers12092682","article-title":"The Neurokinin-1 receptor antagonist aprepitant: an intelligent bullet against cancer?.","volume":"12","author":"Mu\u00f1oz","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.03.025_bib262","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12964-024-01519-8","article-title":"Rolapitant treats lung cancer by targeting deubiquitinase OTUD3","volume":"22","author":"Du","year":"2024","journal-title":"Cell Commun Signal CCS"},{"key":"10.1016\/j.apsb.2025.03.025_bib263","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41467-023-36673-z","article-title":"Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat Commun"},{"issue":"Suppl 2","key":"10.1016\/j.apsb.2025.03.025_bib264","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000049165","article-title":"Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?.","volume":"47","author":"Cascinu","year":"2001","journal-title":"Chemotherapy"},{"key":"10.1016\/j.apsb.2025.03.025_bib265","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41368-024-00308-w","article-title":"Nociceptive adenosine A2A receptor on trigeminal nerves orchestrates CGRP release to regulate the progression of oral squamous cell carcinoma","volume":"16","author":"Jiang","year":"2024","journal-title":"Int J Oral Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib266","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nrurol.2014.67","article-title":"Bladder cancer: faster recovery after radical cystectomy with alvimopan","volume":"11","author":"Clyne","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.apsb.2025.03.025_bib267","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1878-0261.12815","article-title":"Neurotensin receptor 1 signaling promotes pancreatic cancer progression","volume":"15","author":"Takahashi","year":"2021","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib268","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"key":"10.1016\/j.apsb.2025.03.025_bib269","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(54)92559-3","article-title":"Paroxysmal flushing and other symptoms caused by 5-hydroxytryptamine and histamine in patients with malignant tumours","volume":"267","author":"Pernow","year":"1954","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.apsb.2025.03.025_bib270","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.apsb.2025.03.025_bib271","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cellsig.2008.11.012","article-title":"Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells","volume":"21","author":"Watt","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2025.03.025_bib272","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","article-title":"Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors","volume":"45","author":"Qian","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.apsb.2025.03.025_bib273","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib274","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.3390\/ijms21051682","article-title":"Somatostatin analogs in clinical practice: a review","volume":"21","author":"Gomes-Porras","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib275","first-page":"610","article-title":"Thyrotropin-secreting pituitary tumors","volume":"17","author":"Beck-Peccoz","year":"1996","journal-title":"Endocr Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib276","first-page":"1386","article-title":"Somatostatin receptor subtype gene expression in pituitary adenomas","volume":"80","author":"Miller","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2025.03.025_bib277","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.apsb.2025.03.025_bib278","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2011.09.014","article-title":"Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients","volume":"76","author":"Zarogoulidis","year":"2012","journal-title":"Lung Cancer Amst Neth"},{"key":"10.1016\/j.apsb.2025.03.025_bib279","doi-asserted-by":"crossref","first-page":"e695","DOI":"10.1016\/j.clgc.2018.01.019","article-title":"Phase I trial of the combination of docetaxel, prednisone, and pasireotide in metastatic castrate-resistant prostate cancer","volume":"16","author":"Thakur","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib280","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/SLA.0000000000006313","article-title":"Somatostatin versus octreotide for prevention of postoperative pancreatic fistula: the PREFIPS randomized clinical trial: a FRENCH 007-ACHBT study","volume":"280","author":"Gaujoux","year":"2024","journal-title":"Ann Surg"},{"key":"10.1016\/j.apsb.2025.03.025_bib281","doi-asserted-by":"crossref","first-page":"14927","DOI":"10.3748\/wjg.v20.i40.14927","article-title":"Effect of somatostatin in advanced gastric cancer after D2 radical gastrectomy","volume":"20","author":"Song","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.apsb.2025.03.025_bib282","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1186\/s12885-023-10993-1","article-title":"Pharmacological inhibition of neuropeptide Y receptors Y1 and Y5 reduces hypoxic breast cancer migration, proliferation, and signaling","volume":"23","author":"Pascetta","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib283","doi-asserted-by":"crossref","first-page":"19635","DOI":"10.1073\/pnas.1908998116","article-title":"Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload","volume":"116","author":"Ge","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.03.025_bib284","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.biocel.2018.08.010","article-title":"Neurokinin-1 receptor (NK1R) inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-\u03baB axis: shedding new light on resistance to aaprepitant","volume":"103","author":"Bashash","year":"2018","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib285","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1959270","article-title":"Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance","volume":"2016","author":"Robinson","year":"2016","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.apsb.2025.03.025_bib286","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173168","article-title":"A novel effect of aprepitant: protection for cisplatin-induced nephrotoxicity and hepatotoxicity","volume":"880","author":"Un","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.apsb.2025.03.025_bib287","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib288","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5954379","article-title":"A comparison of the efficacy of 5 mg olanzapine and aprepitant in the prevention of multiple-day cisplatin chemotherapy-induced nausea and vomiting","volume":"2022","author":"Liu","year":"2022","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.apsb.2025.03.025_bib289","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","article-title":"The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer","volume":"45","author":"Mu\u00f1oz","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib290","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","article-title":"The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug","volume":"28","author":"Mu\u00f1oz","year":"2010","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.apsb.2025.03.025_bib291","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1016\/j.apsb.2024.06.023","article-title":"Genome-wide pan-GPCR cell libraries accelerate drug discovery","volume":"14","author":"Yang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.03.025_bib292","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2174\/187152009787313828","article-title":"Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours","volume":"9","author":"Marin","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib293","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1016\/j.apsb.2023.02.013","article-title":"Research advances in peptide\u2012drug conjugates","volume":"13","author":"Gong","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.03.025_bib294","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biomedicines9080872","article-title":"Advances and limitations of antibody drug conjugates for cancer","volume":"9","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.apsb.2025.03.025_bib295","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.4155\/fmc.12.76","article-title":"Peptides and peptide conjugates: therapeutics on the upward path","volume":"4","author":"Ahrens","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib296","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.regpep.2004.03.021","article-title":"The development of VIP\u2013ellipticine conjugates","volume":"123","author":"Moody","year":"2004","journal-title":"Regul Pept"},{"key":"10.1016\/j.apsb.2025.03.025_bib297","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0024-3205(02)01741-1","article-title":"VIP-ellipticine derivatives inhibit the growth of breast cancer cells","volume":"71","author":"Moody","year":"2002","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib298","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3762\/bjoc.15.11","article-title":"Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells","volume":"15","author":"Kufka","year":"2019","journal-title":"Beilstein J Org Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib299","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jconrel.2015.04.037","article-title":"A cleavable cytolysin\u2013neuropeptide Y bioconjugate enables specific drug delivery and demonstrates intracellular mode of action","volume":"209","author":"Ahrens","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.03.025_bib300","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1021\/acs.jmedchem.6b00043","article-title":"Double methotrexate-modified neuropeptide Y analogues express increased toxicity and overcome drug resistance in breast cancer cells","volume":"59","author":"B\u00f6hme","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib301","first-page":"821","article-title":"Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide","volume":"47","author":"Carney","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib302","first-page":"927","article-title":"Bombesin\u2013drug conjugates in targeted therapy for small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib303","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1021\/bc050224c","article-title":"Single-drug multiligand conjugates: synthesis and preliminary cytotoxicity evaluation of a paclitaxel-dipeptide \u201cscorpion\u201d molecule","volume":"17","author":"Safavy","year":"2006","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib304","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.apsb.2017.09.008","article-title":"Substance P-modified human serum albumin nanoparticles loaded with paclitaxel for targeted therapy of glioma","volume":"8","author":"Ruan","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.03.025_bib305","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0092-8674(00)80516-4","article-title":"Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P\/CAF and CBP\/p300","volume":"90","author":"Chen","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.03.025_bib306","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s13346-018-00606-x","article-title":"Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells","volume":"9","author":"Accardo","year":"2019","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib307","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.3390\/cancers15112975","article-title":"Peptide receptor radionuclide therapy (PRRT): innovations and improvements","volume":"15","author":"Merola","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.03.025_bib308","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/17474124.2023.2215981","article-title":"Integrated use of 90Y-labeled microspheres and immune checkpoint inhibitors in hepatic tumors: current status and future directions","volume":"17","author":"Filippi","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2025.03.025_bib309","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with gallium-68, lutetium-177, copper-64\/67, actinium-225, and lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2025.03.025_bib310","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2603","article-title":"Radiation-induced bystander signalling in cancer therapy","volume":"9","author":"Prise","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib311","first-page":"1","article-title":"Radiobiology of systemic radiation therapy","volume":"22","author":"Murray","year":"2007","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.apsb.2025.03.025_bib312","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/bc200151q","article-title":"Theranostics: combining imaging and therapy","volume":"22","author":"Kelkar","year":"2011","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.03.025_bib313","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.896287","article-title":"Peptide receptor radionuclide therapy in thyroid cancer","volume":"13","author":"Gubbi","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib314","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib315","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-dotatate in the Phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.apsb.2025.03.025_bib316","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.apsb.2025.03.025_bib317","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1097\/RLU.0000000000002219","article-title":"177Lu-DOTATATE therapy in radioiodine-refractory differentiated thyroid cancer: a single center experience","volume":"43","author":"Roll","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib318","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/cancers14122925","article-title":"The role of [68Ga]Ga-DOTA-SSTR PET radiotracers in brain tumors: a systematic review of the literature and ongoing clinical trials","volume":"14","author":"Palmisciano","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.apsb.2025.03.025_bib319","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13550-020-0612-8","article-title":"Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides","volume":"10","author":"Chastel","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib320","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1021\/acs.molpharmaceut.6b00464","article-title":"Targeting the neuropeptide Y1 receptor for cancer imaging by positron emission tomography using novel truncated peptides","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2025.03.025_bib321","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fendo.2018.00345","article-title":"Neuropeptide G protein-coupled receptors as oncotargets","volume":"9","author":"Moody","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib322","first-page":"81","article-title":"Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer","volume":"19","author":"De Vincentis","year":"2004","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.apsb.2025.03.025_bib323","article-title":"An exploratory study on 99mTc-RGD-BBN peptide scintimammography in the assessment of breast malignant lesions compared to 99mTc-3P4-RGD2","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.03.025_bib324","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0304-3835(03)00082-X","article-title":"The regulation of angiogenesis in neuroblastoma","volume":"197","author":"Chlenski","year":"2003","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2025.03.025_bib325","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jcp.33.2.160","article-title":"Substance P in ovarian carcinoid","volume":"33","author":"Skrabanek","year":"1980","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.apsb.2025.03.025_bib326","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1111\/j.1445-2197.1992.tb06945.x","article-title":"Elevated plasma calcitonin gene-related peptide and the symptoms associated with medullary thyroid cancer","volume":"62","author":"Rubinstein","year":"1992","journal-title":"Aust N Z J Surg"},{"key":"10.1016\/j.apsb.2025.03.025_bib327","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1749-6632.2000.tb06977.x","article-title":"Analysis of VIP and CGRP plasma levels after radiotherapy for treatment of metastasis from prostatic carcinoma","volume":"921","author":"Forsgren","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.apsb.2025.03.025_bib328","first-page":"4636","article-title":"Y1-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets","volume":"61","author":"Reubi","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2025.03.025_bib329","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/ijc.20357","article-title":"Downregulation of KiSS-1 expression is responsible for tumor invasion and worse prognosis in gastric carcinoma","volume":"111","author":"Dhar","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib330","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12943-021-01441-4","article-title":"Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer","volume":"20","author":"Zhu","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2025.03.025_bib331","article-title":"Neuropeptide precursor VGF promotes liver metastatic colonization of G\u03b1q mutant uveal melanoma by facilitating tumor microenvironment via paracrine loops","author":"Ouyang","year":"2024","journal-title":"Adv Sci Weinh Baden"},{"key":"10.1016\/j.apsb.2025.03.025_bib332","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ceb.2018.10.007","article-title":"GPCR homo-oligomerization","volume":"57","author":"Milligan","year":"2019","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.apsb.2025.03.025_bib333","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.931573","article-title":"GPCR heteromers: an overview of their classification, function and physiological relevance","volume":"13","author":"Dale","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.apsb.2025.03.025_bib334","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2012.5","article-title":"Opioid receptor heteromers in analgesia","volume":"14","author":"Costantino","year":"2012","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.apsb.2025.03.025_bib335","doi-asserted-by":"crossref","first-page":"ra54","DOI":"10.1126\/scisignal.2000807","article-title":"Increased abundance of opioid receptor heteromers after chronic morphine administration","volume":"3","author":"Gupta","year":"2010","journal-title":"Sci Signal"},{"key":"10.1016\/j.apsb.2025.03.025_bib336","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2123146119","article-title":"The neuropeptide landscape of human prefrontal cortex","volume":"119","author":"Zhong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525001625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525001625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T21:28:47Z","timestamp":1747344527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525001625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":336,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2211383525001625"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.03.025","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The neuroscience of cancer: Focus on neuropeptidergic systems","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}